Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698989 | 0.87 | KDM4E (0.47) | DRD2KDM4E | |
| SCHEMBL19289053 | 0.84 | HRH3 (0.42) | HTR2ADRD2KCNH2HRH3SIGMAR1 | |
| SCHEMBL14945599 | 0.83 | CYP2D6 (0.48) | HTR2ADRD2KCNH2HTR2CHRH3 | |
| SCHEMBL14945598 | 0.83 | HTR2A (0.42) | HTR2ADRD2KCNH2HTR2CHRH3 | |
| SCHEMBL13005003 | 0.83 | AKT1 (0.48) | HTR2ADRD2KCNH2HTR2CHRH3 | |
| SCHEMBL8669756 | 0.81 | HRH3 (0.43) | HTR2ADRD2KCNH2HTR2CHRH3 | |
| SCHEMBL13005005 | 0.80 | HTR2A (0.63) | HTR2ADRD2KCNH2HTR2CHRH3 | |
| SCHEMBL5313163 | 0.79 | HDAC3 (0.45) | HTR2AKCNH2HRH3CYP2D6 | |
| SCHEMBL5317315 | 0.78 | HTR2A (0.64) | HTR2ADRD2KCNH2HTR2CSIGMAR1 | |
| SCHEMBL6849624 | 0.76 | PKM (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HTR2A 126/4885DRD2 337/4885KCNH2 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.